← All trials
NCT03195387
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 31, 2018
- Primary completion
- Sep 30, 2018
- Completion date
- Dec 31, 2018
- First posted
- —
- Last posted
- —
- Enrollment
- —
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Medicines for Malaria VentureLead sponsor
- ICONCollaborator
- Sanaria Inc.Collaborator
- University of Cape TownCollaborator
- University of TuebingenOverall official - principal investigator
- PrimeVigilance LTDCollaborator
- PTx SolutionsCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.